Dendreon, Ulta Beauty: After-Hours Trading

NEW YORK ( TheStreet) -- Shares of Dendreon ( DNDN) rose in late trades on Thursday after the drug developer said it's laying off 500 workers as part of a restructuring.

The Seattle-based company also said gross revenue for its Provenge prostate cancer drug totaled $22 million in August, and that Hans Bishop had exited the chief operating officer post. It expects the layoffs to result in a cost of roughly $21 million, including a non-cash charge of $5 million related to stock-based compensation expenses.

The stock was last quoted at $11.15, up 2.5%, on volume of more than 400,000, according to Nasdaq.com.

"While the last month has been difficult for our employees, these cost reductions are necessary to ensure the long-term growth of our company, and I am grateful to our dedicated and passionate employees who are the driving force behind Dendreon," said Mitchell Gold, Dendreon's president and chief executive officer, in a statement.

The shares closed Thursday's regular session at $10.88, a decline of nearly 7% on the day. Year-to-date, the stock has lost almost 70%. The company has reported wider than expected losses for the past eight quarters, and profitability is still a long ways away.

"Given the current cash balance and the reduced levels of spending following the restructuring, Dendreon expects to have sufficient cash to enable the company to achieve a cash flow break even position in the United States at an annual run rate of approximately $500 million in revenue," the company said on Thursday.

So far in 2011, the company has reported revenue totaling roughly $107 million through its fiscal second quarter ended in June. The average estimate of analysts polled by Thomson Reuters is for revenue of $218.7 million for the full year.

Ulta Beauty

Another mover to the upside in the extended session was Ulta Beauty ( ULTA), which gained 1% to $60.50 on volume of nearly 300,000 after posting better than expected quarterly results.

The Bolingbrook, Ill.-based cosmetics retailer said it earned $23.9 million, or 38 cents a share, in its fiscal second quarter ended in July as total sales jumped 22.6% year-over-year to $394.6 million and same-store sales improved 11.3%.

Wall Street's consensus view was calling for a profit of 32 cents a share in the quarter on sales of $384.2 million.

For its fiscal third quarter ending in October, Ulta forecast earnings of 36 to 38 cents a share with total sales ranging between $400 million and $407 million and an increase of between 6%-8% in same-store sales. The average analysts' view is for a profit of 34 cents a share in the current quarter.

Other stocks garnering trading interest late Thursday included VeriSign ( VRSN), which fell sharply on news of the surprise resignation of its chief financial officer; and ABM Industries ( ABM), which lost 11% to $17.60 on light volume after the New York-based facility services provider gave a weak outlook for the rest of the year, citing pricing pressure because of the weak economy and higher fuel and unemployment insurance costs.

-- Written by Michael Baron in New York.

Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

More from Opinion

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense

Amazon's Assault on Grocery Stores Will Have a Profound Impact on Many

Amazon's Assault on Grocery Stores Will Have a Profound Impact on Many

It's Dumb to Think There Aren't Already Monopolies in Big Tech

It's Dumb to Think There Aren't Already Monopolies in Big Tech

Google's EU Battles Are Hardly a Reason to Panic

Google's EU Battles Are Hardly a Reason to Panic